Skip to main content

Table 2 Parameter estimates

From: A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients

Parameters

Units

Estimate

RSE (%)

Bootstrap estimate

Bootstrap

95% CI

Population parameters

 Clearance (CL)

L/day

0.211

3.5

0.211

0.196 to 0.226

 Central volume of distribution (V1)

L

3.46

5.8

3.46

3.09 to 3.83

 Peripheral volume of distribution (V2)

L

3.46

5.8

3.46

3.09 to 3.84

 Inter-compartmental clearance (Q)

L/day

0.48

< 0.1

0.48

0.48 to 0.48

Covariate effects

 Female gender on CL

–

−0.17

29.1

−0.17

−0.27 to −0.06

 BSA effect on CL

–

0.97

24.1

0.96

0.48 to 1.45

 Albumin effect on CL

–

−1.34

19.8

−1.33

−1.83 to − 0.86

Between-subject variability

 Clearance (CL)

CV%

30.7

9

30.3

24.8 to 35.6

 Residual unexplained variability

 Proportional error

CV%

31.8

8

31.8

29.1 to 34.2

  1. Population parameters, covariate effects and between-subject variability according to the final population pharmacokinetic model (Mf). Abbreviations: CL clearance, RSE relative standard error, CV% percentage coefficient of variation, CI confidence interval. The shrinkage of the between-subject variability of clearance and the proportional error was 9.2 and 4%, respectively